Objectives. Recent studies have shown that the slightly elevated circulating levels of ketone bodies (KBs) played a significant role in the treatment of various diseases. This study is aimed at investigating the association between different levels of KBs and kidney function in patients with type 2 diabetes mellitus (T2DM).

Methods. A retrospective study of 955 patients with T2DM (426 women and 529 men) admitted to our hospital from December 2017 to September 2019 was conducted. Patients were divided into different groups in line with the levels of KBs (low-normal group: 0.02-0.04 mmol/L, middle-normal group: 0.05-0.08 mmol/L, high-normal group: 0.09-0.27 mmol/L, and slightly elevated group: >0.27 and <3.0 mmol/L).

Results. In the present study, individuals with high-normal levels of KBs had the lowest risk of diabetic kidney disease (DKD) and increased peak systolic velocity (PSV); those with middle-normal levels of KBs had the lowest risk of increased renal arterial resistive index (RI), with a positive correlation between increased α1-microglobulin and KB concentration. In addition, the indicators of glomerulus, renal tubules, and renal arteries were all poor with slightly elevated circulating levels of KBs, and KB concentration lower than 0.09 mmol/L can be applied as the threshold for low risk of renal function damage.

Conclusions. In summary, slightly elevated circulating levels of ketone bodies are not of benefit for renal function in patients with type 2 diabetes mellitus.

1. Introduction

Diabetic kidney disease (DKD) is one of the most important complications of diabetes, as well as the main reason of end-stage renal disease and renal replacement therapy, which remarkably reduces the quality of life and increases the mortality of diabetic patients [1]. DKD risk factors can be classified as irreversible factors (e.g., age, sex, and duration of diabetes) and modifiable factors (e.g., hyperglycemia, hypertension, dyslipidemia, and smoking) [2]. Besides, the established protective factors of DKD include blood sugar control, blood pressure control, and reduction of urine protein.

Ketone bodies (KBs) are produced predominantly in the liver and are then transported to extrahepatic tissues [3, 4]. Interestingly, renal ketogenesis has been inferred in diabetic animal models and is regarded as a protective mechanism to prevent renal ischemia-reperfusion injury [5]. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of oral hypoglycemic drugs used for the management of type 2 diabetes mellitus (T2DM). A relevant feature of SGLT-2 inhibitors in the treatment of diabetic patients is an increase in circulating levels of KBs, which plays a significant role in the cardiovascular and kidney protection because of the use of KBs as energy substrates and their potential interactions with G-protein coupled receptors and other signaling pathways [6]. In addition, recent clinical studies have demonstrated that slightly elevated circulating levels of KBs play a significant role in the treatment of various diseases, such as...
heart failure, neurodegenerative disease, and cancer [3, 4, 6, 7]. However, some studies suggested that microvascular complications were found to be increased in diabetic patients who had elevated ketones compared to those with normal ketone levels [8].

To date, there are limited number of studies that have concentrated on the potential relationship between KBs and kidney in T2DM patients. To our knowledge, β-hydroxybutyric acid (βHBA) accounted for 78% of the KB component [9]; therefore, the concentration of βHBA is referred for the concentration of KBs. The present study is aimed at investigating the relationship between different levels of KBs and kidney in patients with T2DM and evaluating whether the slightly elevated circulating levels of KBs have a positive influence on kidney in patients with T2DM.

2. Materials and Methods

2.1. Study Population. In this study, a total of 955 patients (426 women and 529 men) were recruited from the Endocrinology Department of the First Affiliated Hospital of Fujian Medical University from December 2017 to September 2019 who met the 1999 World Health Organization (WHO) diagnostic criteria for type 2 diabetes and have the data of ketone bodies. (Supplemental Fig. 1). The diagnosis of T2DM was diagnosed based on the criteria presented by the American Diabetes Association [10]. Exclusion criteria were type 1 diabetes, gestational diabetes, diabetic ketoacidosis [11], hyperosmolar nonketotic coma, hepatic failure, fasting [12], patients who received SGLT-2 inhibitors, or who lacked data related to the levels of KBs. This study was approved by the ethics committee of the First Affiliated Hospital of Fujian Medical University, and all of the participants provided signed informed consent.

2.2. Measurement. Data describing the demographic characteristics, the duration of disease onset, lifestyle and medical histories, and medication histories were collected from medical records. Blood pressure (BP) was measured after 15 min of rest. Body weight and height were measured with the patient barefoot and wearing light clothes. Body mass index (BMI, kg/m²) was defined as weight in kilograms divided by square of the height in meters. The following factors were measured in all study subjects after 10 h of overnight fasting: fasting plasma glucose (FPG), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), serum creatinine concentration (SCr), and βHBA, as well as routine hematological and biochemical parameters. Glycated hemoglobin A1c (HbA1c) level was detected by high-performance liquid chromatography (HPLC; VARIANTTM II; BIO-RAD Laboratories Inc., Hercules, CA, USA). A 75 g oral glucose tolerance test (OGTT) was performed as well. Plasma glucose was measured by glucose oxidase method using the AU2700 analyzer (Olympus Corporation, Tokyo, Japan) and specific reagents. The urinary albumin-to-creatinine ratio (UACR) was calculated as albumin concentration (mg/L) divided by creatinine concentration (g/L) [10]. The eGFR was calculated by the CKD-EPI creatinine equation (2009) that can be expressed as a single equation:

\[
141 \times \min (\text{SCr}/\kappa, 1)^{\alpha} \times \max (\text{SCr}/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}} [x \times 1.018 \text{ if female } x \times 1.159 \text{ if black}], \text{ where SCr is serum creatinine, } \kappa \text{ is 0.7 for females and 0.9 for males, } \alpha \text{ is } -0.329 \text{ for females and } -0.411 \text{ for males, min is the minimum of SCr/} \kappa \text{ or 1, and max is the maximum of SCr/} \kappa \text{ or 1 [13]. Urine protein (PRO) and urine specific proteins, including } \alpha_1 \text{-microglobulin (} \alpha_1 \text{-MG), urinary immunoglobulin G (U-IgG), and urinary transferrin (TRU), were measured from the first-void of the early morning urine sample. Renal vascular parameters were determined by color Doppler ultrasound (DEXA, Lunar Prodigy scanner; GE Lunar Corporation, Madison, WI, USA).}

2.3. Diagnostic Criteria. DKD was diagnosed by the presence of eGFR < 60 mL/min and/or UACR > 30 mg/g for >3 months. [10, 12–14]. Hypertension (HT) was defined as systolic BP (SBP) ≥ 140 mmHg and/or diastolic BP (DBP) ≥ 90 mmHg and/or treatment with antihypertensives [10, 15, 16]. Reduced renal artery diameter was identified as arterial diameter of <0.5 cm [17]. Increased peak systolic velocity (PSV) was defined as peak renal arterial blood flow rate of >100 cm/s [18, 19]. Increased renal arterial resistive index (RI) was calculated as RI > 0.7 [20]. In the present study, reference interval for a1-MG is lower than 15 mg/L [21]. Furthermore, we defined a1 – MG > 15 mg/L as increased a1-microglobulin. Renal function damage was defined as damage to one of the glomerulus, renal tubules, and renal arteries.

2.4. Statistical Analysis. The SPSS 20.0 software (IBM, Armonk, NY, USA) was used to perform statistical analysis. Continuous variables were expressed as mean ± standard deviation or median (P25–P75), and categorical variables were presented as count and percentage. The patients within the normal range of KBs were divided into tertiles (low-normal KB group: 0.02–0.04 mmol/L; middle-normal KB group: 0.05–0.08 mmol/L; high-normal KB group: 0.09–0.27 mmol/L). In addition, the slightly elevated KB concentration was higher than the normal concentration and lower than the concentration of ketoacidosis. Therefore, the slightly elevated circulating levels of KBs were defined as greater than 0.27 mmol/L, while less than 3.0 mmol/L [11, 22]. Differences in the baseline characteristics were analyzed by ANOVA test and post hoc least significant difference t-test, Kruskal–Wallis test and Nemenyi post hoc test, and the chi-squared test and partitions of the chi-squared test post hoc test. Multiple linear regression analysis was performed to identify independent factors for KBs. Binary logistic regression analysis was employed to determine whether different levels of KBs are independently associated with glomerulus, renal tubules, and renal arteries. The contingency coefficient C was calculated to quantify the relationship between KBs and glomerulus, renal tubules, and renal arteries. The sensitivity and specificity of the KB measurement at the diagnosis of renal function damage were calculated using the receiver operating characteristic (ROC) analyses. The best cut-off value was determined by the Youden index [sensitivity + specificity – 1]. P < 0.05 was considered statistically significant.
3. Results

3.1. Study Population Characteristics. The clinicopathological characteristics of 955 T2DM patients were categorized according to their levels of KBs as shown in Table 1. In the four groups, patients in the high-normal KB group demonstrated the highest eGFR ($P < 0.01$) and the lowest incidence rate of DKD ($P < 0.05$). Significant changes were observed in age, sex, smoking [23], drinking [24], heart rate (HR), fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG), HbA1c, TG, albumin (ALB), a1-MG, and urine protein (PRO). However, no significant differences were observed in SBP, DBP, TC, LDL-C, HbA1c, BUN, SCr, UACR, TRU, and OADs. In addition, multiple linear regression analysis showed that sex, BMI, BUN, 2hPG, HR, and drinking were significantly associated with KBs in T2DM patients (all $P < 0.05$), and 2hPG was the most influence on KBs according to standardization coefficient (supplemental table 1).

3.2. Association of KB Concentration with DKD. An association was found between the levels of KBs and DKD. A significant difference in the prevalence of DKD was observed in the study (low-normal KB group, 35.10%; middle-normal KB group, 32.30%; high-normal KB group, 30.00%; slightly elevated KB group, 47.10%; $P = 0.031$; Figure 1).

Table 2 shows the results of binary logistic regression analysis for DKD according to the concentration of KBs. In the unadjusted Model #1, diabetic patients in the normal KB groups (low-normal KB group: odds ratio (OR) = 0.683, $P = 0.043$; middle-normal KB group: OR = 0.631, $P = 0.015$; high-normal KB group: OR = 0.602, $P = 0.004$) demonstrated a significantly lower risk of DKD when compared to those patients in the slightly elevated KB group. After adjusting the age, duration of diabetes, SBP, DBP, HR, TC, TG, LDL-C, HbA1c, BUN, ALB, BMI, smoking, and drinking, Model #3 demonstrated that diabetic patients in the high-normal KB group had the lowest risk of DKD (OR = 0.435, $P = 0.032$).

3.3. Association of KB Concentration with Glomerulus, Renal Tubules, and Renal Arteries. In the present study, the OR of increased a1-MG was positively associated with KB concentration, and diabetic patients in the slightly elevated KB group have a significantly highest risk of increased a1-MG (OR = 3.106, $P \leq 0.001$; Figure 2(a)) compared with the low-normal KB group after adjusting for the confounding factors. Renal vascular indicators were detected by color Doppler ultrasound in 455 T2DM patients. The binary logistic regression analyses indicated that T2DM patients in the high-normal KB group exhibited a significantly lower risk of increased PSV (OR = 0.581, $P = 0.033$; Figure 2(b)), and those in the middle-normal KB group had a remarkably lower risk of increased RI (OR = 0.379, $P = 0.002$; Figure 2(c)). There were no significant differences in other groups when compared with the low-normal KB group after adjusting for the abovementioned confounding factors. In addition, compared with the low-normal KB group, no significant relationship was observed between the KB concentration with the risk of reduced diameter of renal artery (middle-normal group: OR = 1.107, $P = 0.708$; high-normal group: OR = 0.800, $P = 0.398$; slightly elevated group: OR = 1.476, $P = 0.382$; Figure 2(d)). The relationship of KB levels was found with the prevalence of DKD (correlation coefficient $= 0.096$, $P = 0.031$), increased a1-microglobulin (correlation coefficient $= 0.160$, $P \leq 0.001$), increased renal arterial resistive index (correlation coefficient $= 0.212$, $P \leq 0.001$), and increased peak systolic velocity (correlation coefficient $= 0.097$, $P = 0.245$), showing the renal tubule is more influenced by KBs (Supplemental fig. 2). Furthermore, in the ROC curve of KBs for detection of renal function damage, the best KB cut-off value, as assessed by the Youden index, was 0.09 mmol/L, which provided a sensitivity of 36% and a specificity of 74% (Supplemental fig. 3).

4. Discussion

In the present study, DKD and PSV were found to be significantly decreased in the high-normal KB group; RI was notably reduced in the middle-normal KB group, a1-MG was positively associated with KB concentration, and the indicators of glomerulus, renal tubules, and renal arteries were all poor in the slightly elevated KB group, suggesting that there is no evidence indicating that slightly elevated circulating levels of KBs have a positive influence on patients with T2DM.

In the current research, individuals with slightly elevated circulating levels of KBs had the highest risk of DKD suggesting that a slight increase in KB level is a potential risk factor for DKD. Moreover, the eGFR value was the lowest in the slightly elevated KB group, suggesting that slightly elevated circulating levels of KBs showed no significant effect on renal blood flow. The results also unveiled that slightly elevated levels of KBs do not play a protective role in diabetic microangiopathy. This is inconsistent with the previous reported findings related to diabetic macroangiopathy, especially cardiovascular disease [25–28]. Brownlee has pointed out that excessive production of mitochondrial superoxide is a common mechanism in diabetes complications [29]. Additionally, diabetic macrovascular and microvascular complications often coexist in patients with T2DM, and the two often share common risk factors, such endothelial cell injury [30, 31]. However, it is highly essential to explore whether the behavior of endothelial cells in different areas is accompanied with a great heterogeneity [32]. This is an important mechanism for the slight elevation of KB levels accompanied with significant differences in microvascular and macrovascular complications. Other possible mechanism is that the high level of KBs is often associated with high blood sugar level, and the elevated levels of KBs activated varied harmful pathological complications, resulting in noxious stimuli that cause cell injury [8]. In addition, the result revealed that the prevalence of DKD and the value of eGFR shared the same trend of variability, and both showed a significant protective signal at high-normal levels of KBs and a negative effect at slightly elevated KB levels, while UACR and KB concentrations had no obvious relationship, suggesting that the KBs and eGFR are more strongly associated with the relationship between KBs and DKD. It is well known that RI, PSV, and
| Ketone body concentration (mmol/L) | 0.02-0.04 | 0.05-0.08 | 0.09-0.27 | >0.27 | P  |
|-----------------------------------|-----------|-----------|-----------|-------|----|
| No of subjects                    | 350       | 260       | 260       | 85    |    |
| Age (years old)                   | 63.64 ± 11.26 | 61.05 ± 12.04↑ | 60.12 ± 14.57↑ | 61.29 ± 14.88 | 0.025* |
| Male (n (%))                      | 163 (46.6%) | 143 (55.0%) | 165 (63.5%) | 58 (68.2%) | ≤0.001* |
| Duration of diabetes (year)       | 10.50 ± 7.72 | 9.90 ± 7.21 | 10.06 ± 7.66 | 8.89 ± 6.91 | 0.339 |
| Smoker                            | 57 (16.3%)  | 47 (18.1%)↑ | 69 (26.5%)↑ | 21 (25.0%)↑‡ | 0.009* |
| Alcohol                           | 14 (4.0%)   | 16 (6.2%)↑ | 20 (7.8%)↑ | 11 (13.1%)↑ | 0.015* |
| BMI (kg/m²)                       | 24.71 ± 3.83 | 25.05 ± 4.54 | 24.58 ± 3.94 | 23.36 ± 3.95↑‡ | 0.023* |
| Prevalence of hypertension n (%)  | 211 (60.5%) | 146 (56.2%) | 142 (54.6%) | 47 (56.0%)   | 0.495 |
| SBP (mmHg)                        | 134.9 ± 22.2 | 134.8 ± 19.8 | 135.8 ± 18.8 | 135.3 ± 22.6 | 0.941 |
| DBP (mmHg)                        | 77.9 ± 11.4 | 78.15 ± 10.6 | 79.51 ± 11.1 | 79.58 ± 10.7 | 0.253 |
| HR (bpm)                          | 71.10 ± 12.31 | 72.08 ± 11.17 | 74.45 ± 12.76↑† | 77.57 ± 13.65↑† | ≤0.001* |
| FPG (mmol/L)                      | 7.26 ± 3.26 | 7.99 ± 3.14↑ | 8.73 ± 3.83↑‡ | 8.79 ± 4.37↑‡ | ≤0.001* |
| 2hPG (mmol/L)                     | 12.05 ± 4.19 | 12.25 ± 4.11 | 13.61 ± 4.13↑‡ | 13.37 ± 5.14↑‡ | ≤0.001* |
| Hba1c (%)                         | 8.55 ± 2.27 | 9.04 ± 2.40↑ | 9.57 ± 2.61↑‡ | 9.65 ± 2.77↑‡ | ≤0.001* |
| TG (mmol/L)                       | 1.33 (0.90-1.97) | 1.36 (0.97-2.07) | 1.40 (1.02-2.18) | 1.16 (0.84-1.87) | 0.032* |
| TC (mmol/L)                       | 4.34 ± 0.98 | 4.42 ± 1.23 | 4.57 ± 1.39 | 4.44 ± 1.65 | 0.159 |
| LDL (mmol/L)                      | 2.67 ± 0.84 | 2.80 ± 1.05 | 2.85 ± 1.07 | 2.71 ± 1.05 | 0.125 |
| ALB (g/L)                         | 39.04 ± 4.18 | 39.99 ± 4.52↑ | 39.59 ± 4.86 | 37.46 ± 6.06↑† | 0.001* |
| BUN (mmol/L)                      | 6.42 ± 3.86 | 6.44 ± 3.52 | 6.23 ± 3.19 | 6.64 ± 4.82 | 0.808 |
| SCr (umol/L)                      | 60.85 (49.38-76.70) | 59.80 (47.93-73.95) | 61.70 (49.08-74.00) | 65.20 (46.30-83.00) | 0.572 |
| eGFR (mL/min)                     | 92.21 ± 26.56 | 96.09 ± 26.52 | 98.33 ± 28.00↑ | 92.89 ± 31.36 | 0.009* |
| UACR (mg/g)                       | 13.65 (6.27-94.39) | 13.49 (6.45-62.62) | 16.81 (7.42-83.76) | 28.80 (10.98-145.92) | 0.055 |
| α1-MG (mg/L)                      | 10.20 (4.19-20.50) | 9.18 (4.30-21.05) | 11.10 (4.78-24.05) | 21.10 (8.93-55.47)↑‡ | ≤0.001* |
| U-IgG (mg/L)                      | 8.42 (4.41-23.98) | 6.82 (4.48-15.92) | 7.31 (4.27-19.70) | 14.20 (5.36-45.92)↑‡ | 0.020* |
| TRU (mg/L)                        | 9.97 (4.31-36.67) | 6.77 (3.34-22.45) | 8.96 (4.00-46.20) | 10.07 (3.43-61.22)↑† | 0.386 |
| DKD (%)                           | 123 (35.1%) | 84 (32.3%)↑ | 78 (30.0%) | 40 (47.1%)↑‡ | 0.031* |
| Increased α1-MG                   | 110 (36.3%) | 79 (32.8%)↑ | 94 (41.2%)↑ | 45 (62.5%)↑‡ | ≤0.001* |
| PRO                               | -          | 223 (67.0%) | 165 (65.5%) | 160 (66.4%) | 38 (46.9%) |
|                                  | +          | 110 (33.0%) | 87 (34.5%) | 81 (33.6%) | 43 (53.1%)↑‡ |
| Reduced renal artery diameter (%) | 122 (70.5%) | 83 (69.7%) | 81 (63.8%) | 27 (75.0%) | 0.489 |
| Increased PSV (%)                 | 81 (48.5%) | 46 (40.4%) | 48 (38.7%) | 17 (51.2%) | 0.245 |
| Increased RI (%)                  | 104 (62.3%) | 43 (37.7%) | 75 (60.5%)↑‡ | 14 (42.4%)↑‡ | ≤0.001* |

Type of antidiabetic therapy 0.236

- None
- OADs
- Insulin
- OADs + insulin

Post hoc analysis: ↑ compared with the ketone body concentration 0.02-0.04 group, P < 0.05; † compared with the ketone body concentration 0.05-0.08 group, P < 0.05; ‡ compared with the ketone body concentration 0.09-0.27 group, P < 0.05; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; FPG: fasting plasma glucose; 2hPG: 2 h 75 g oral glucose tolerance test plasma glucose; Hba1c: glycated hemoglobin; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; BMI: body mass index; S. Cr.: serum creatinine; GFR: glomerular filtration rate; UACR: urinary albumin-to-creatinine ratio; α1-MG: α1-microglobulin; U-IgG: urinary immunoglobulin G; TRU: urinary transferrin; PRO: urine protein; DKD: diabetic kidney disease; PSV: peak systolic velocity; RI: resistive index; OADs: oral antidiabetic drugs. *P < 0.05.
eGFR were intimately linked with renal perfusion [33], and the study has shown a correlation between RI, PSV, and KBs, which also supports the above conclusions.

It is well known that the patients with DM are at high risk of developing atherosclerotic renal artery stenosis (RAS) [34]. However, there is lack of consensus on the relationship between the levels of KBs and renal artery. A number of scholars have demonstrated that slightly elevated circulating levels of KBs can reduce renal ischemia-reperfusion injury through anti-inflammatory effects, and it also plays a positive role in the treatment of acute kidney injury [5]. In the present study, it was revealed that heart rate showed association with KB concentration, while cases with high-normal levels of KBs had the lowest risk of increased PSV, and those with middle-normal levels of KBs had the lowest risk of increased RI [35]. Moreover, RI is not only a risk factor of glomerular and tubular damage and kidney disease progression but also a marker of endothelial dysfunction [36]. The results of the present study were consistent with those reported previously, due to the following reasons. Firstly, diabetic heart is characterized by failure of insulin to increase glucose uptake and increasingly relies on free fatty acids (FFAs) as a source of energy, while KB as a supplementary source of energy plays a significant role in heart health [28, 37, 38]. Secondly, although the structure of the endothelium is similar in various vascular segments, the endothelial behavior in the endothelial territories is significantly different, which is independent of several factors [32]. Thirdly, hyperketonemia and hyperglycemia often coexist in T2DM patients, complicating the relationship between the levels of KBs and renal artery. Finally, the slightly elevated circulating levels of KBs resulted in macrophage and lymphocyte activation, increased risk of vascular inflammation, and perturbation of capillary endothelial cells [37, 38]. In addition, PSV and RI were associated with higher levels of Doppler ultrasound parameters of RAS; it is interesting that the distribution of PSV (lowest in high-normal range) and RI (lowest in middle-normal group) is different. The underlying reason for the inconsistency may be that RI reflects the macroscopic perfusion resistance of the distal vascular system of the monitoring point, while PSV reflects the hemodynamic parameters of the monitoring point and can be affected by the conditions of arteries upstream or downstream of a stenosis [35, 39]. Therefore, RI has a higher sensitivity to the effects of ketone bodies on renal arteries.

It is noteworthy that the renal tubule plays a pivotal role in the pathogenesis of DKD and actively participates in the progression of end-stage renal disease (ESRD) [1, 40]. Studies have demonstrated that podocyte damage and proximal tubule dysfunction biomarkers could be validated as a practical approach to the diagnosis of early DKD [32, 40]. Besides, α1-MG is important parameter for evaluating renal tubular injury, and its increased values reflect tubular damage and can be detected in early DKD [41]. SGLT-2 inhibitors are antidiabetic agents that reduce hyperglycemia by impairing glucose reabsorption in the proximal tubule of the kidney and increase glucosuria. SGLT2 inhibitors have shown to reduce glucotoxicity in isolated proximal tubule cells and also to attenuate the expression of markers of overall kidney damage in experimental animal models of diabetes [42–44]. In the current study, the value of α1-MG reached maximum when the KB level was slightly elevated, which indicated that in contrast to the complex multifactor renal protection mechanism of SGLT-2 inhibitors, a slightly elevated KB level does not play a role in kidney protection, while it is a significant contributor in increasing the risk of tubular injury.

In the present study, both the prevalence of DKD and the OR of renal artery Doppler ultrasound parameters have a U-shaped distribution with the KB concentration, whereas the OR of increased α1-MG was positively associated with KB concentration, with slightly elevated levels of KBs having the least benefit for the glomerulus, renal tubules, and renal arteries. The specific reasons for this distribution may be as follows. Firstly, DKD is classically regarded to be manifested as glomerulosclerosis, tubulointerstitial fibrosis, and renal vascular disease [45]. In addition, the different injury mechanisms of glomerulus, renal tubules, and renal arteries induce different degrees of damage and different features in various stages of kidney disease. Secondly, many studies have revealed that apart from serving as energy fuels, KBs play critical roles as modulators of inflammation and oxidative stress [4]. Within a certain range, as the concentration of KBs increases, its effect is enhanced, anything beyond that
would lead to the protective effect decreased gradually. The optimal KB concentration of function protection varies among glomerulus, renal tubules, and renal arteries. This study demonstrated that when the KB concentration is lower than 0.09 mmol/L, it can be perceived as a cut-off for low risk of renal function damage. Thirdly, although the benefits of KBs have been confirmed, nevertheless excessive KBs can cause adverse effects. The elevated ketones in a manner that is detrimental and injurious inducing oxidative stress and eliciting inflammatory responses which interfere the normal cellular function and mediate cellular damage, also play a prominent role in the development of complications associated with diabetes [8]. In addition, the presence of elevated ketones with high glucose can engender more damage to the cells compared to that of just high glucose alone [8]. Finally, interestingly, some studies have clarified that there is a U-shaped relationship between HbA1c and mortality and when HbA1c levels between 7 and 8% seem to be associated with the highest survival rates in DKD patients [46]. The ACCORD, VADT, and ADVANCE studies, which primarily focused on intensive blood sugar control in patients with T2DM, did not find any benefits in clinical renal outcomes [47]. The conclusion is consistent with the results of KBs, suggesting that maintaining blood glucose and blood ketone levels to a certain extent has a more protective effect on DKD.

We need more dynamic blood glucose indicators and more samples to explore the accurate ranges and specific mechanisms. However, there is a limitation in the present study with regard to the lack of DKA patients’ data and the pathological indexes. Besides, a number of patients missed undergoing vascular color Doppler ultrasound. Additionally, as this was a cross-sectional study, causal associations between the levels of KBs and kidney function in patients with T2DM could not be allowed. Hence, further in-depth studies should be conducted to confirm these findings and eliminate the above-mentioned shortcomings.

The major strength of the present study was comprehensive assessment of the relationship between the levels of KBs and kidney function in patients with T2DM. We demonstrated that individuals with high-normal levels of KBs had the lowest risk of DKD and increased PSV; those with middle-normal levels of KBs had the lowest risk of increased RI, with a positive correlation between increased α1-microglobulin and KB concentration. In addition, the indicators of glomerulus, renal tubules, and renal arteries were all poor with slightly elevated circulating levels of KBs, and KB concentration lower than 0.09 mmol/L can be applied as the threshold for low risk of renal function damage. In summary, slightly elevated circulating levels of ketone bodies are not of

![Figure 2](https://example.com/figure2.png)

**Figure 2**: (a) Adjusted ORs of increased α1-microglobulin in different KB concentration-based groups. (b) Adjusted ORs of increased peak systolic velocity of renal artery in different KB concentration-based groups. (c) Adjusted ORs of increased renal arterial resistive index in different KB concentration-based groups. (d) Adjusted ORs of reduced renal artery diameter in different KB concentration-based groups. Adjusted for age, duration of diabetes, SBP, DBP, HR, TC, TG, LDL-C, HbA1c, BNU, ALB, BMI, smoking, and drinking.
benefit for kidney function in patients with type 2 diabetes mellitus. Therefore, the circulating levels of KBs can be used for detecting and predicting the kidney function in patients with T2DM.

Data Availability
The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest
We declare that we have no conflict of interest. None of the authors have any potential conflicts of interest.

Authors’ Contributions
Yongze Zhang is co-first author.

Acknowledgments
We are grateful to the patients for their help and willingness to participate in the study. The Central Government Special Funds for Local Science and Technology Development (2018L 3007) and the Diabetes Fund from Chinese Society of Microcirculation (TW-2018P002) financially supported this work.

Supplementary Materials
Supplemental Table 1: assessment of affected factors in KBs by multiple linear regression. Supplemental Figure 1: flow-chart of patient selection. Supplemental Figure 2: the contingency coefficient (C) is used to evaluate the association of KB concentration with glomerulus, renal tubules, and renal arteries. Supplemental Figure 3: ROC analysis of KBs to indicate renal function damage for patients with type 2 diabetes mellitus. (Supplementary Materials)

References
[1] F. Huang, Q. Wang, F. Guo et al., “FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease,” eBioMedicine, vol. 48, pp. 491–504, 2019.
[2] R. Z. Alicic, M. T. Rooney, and K. R. Tuttle, “Diabetic kidney disease: challenges, progress, and possibilities,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2032–2045, 2017.
[3] A. J. Murray, N. S. Knight, M. A. Cole et al., “Novel ketone diet enhances physical and cognitive performance,” The FASEB Journal, vol. 30, no. 12, pp. 4021–4032, 2016.
[4] P. Puchalska and P. A. Crawford, “Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics,” Cell Metabolism, vol. 25, no. 2, pp. 262–284, 2017.
[5] T. Tajima, A. Yoshifuji, A. Matsui et al., “β-hydroxybutyrate attenuates renal ischemia-reperfusion injury through its anti-pyroptotic effects,” Kidney International, vol. 95, no. 5, 2019.
[6] V. Lu Vallon and S. C. Thomson, “Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition,” Diabetologia, vol. 60, no. 2, pp. 215–225, 2017.
[7] G. Voros, J. Ector, C. Garweg et al., “Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling,” Circulation. Heart Failure, vol. 11, no. 12, article e004953, 2018.
[8] P. Kanikarla-Marie and S. K. Jain, “Hyperketonemia and ketois increase the risk of complications in type 1 diabetes,” Free Radical Biology & Medicine, vol. 95, pp. 268–277, 2016.
[9] C. J. Ge, J. Yang, and Q. Wang, “Clinical significance of rapid blood ketone versus urine ketone bodies detection in diabetic ketosis diagnosis and treatment,” Chinese Journal of Diabetes, vol. 22, no. 12, pp. 1116–1118, 2014.
[10] Y. Zhang, Y. Guo, X. Shen, F. Zhao, and S. Yan, “Lower body mass index is not of more benefit for diabetic complications,” Journal of diabetes investigation, vol. 10, no. 5, pp. 1307–1317, 2019.
[11] L. Gao, Y. Li, D. Fei et al., “Prevalence of and risk factors for diabetic ketosis in Chinese diabetic patients with random blood glucose levels >13.9 mmol/L: results from the CHina study in pREvalence of diabetiC Ketosis(CHECK) study,” Journal of Diabetes, vol. 10, no. 3, pp. 249–255, 2018.
[12] S. Brandhorst, I. Y. Choi, M. Wei et al., “A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan,” Cell metabolism, vol. 22, no. 1, pp. 86–99, 2015.
[13] I. Masson, M. Flament, N. Maillard et al., “MDR versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients,” Transplantation, vol. 95, no. 10, pp. 1211–1217, 2013.
[14] K. R. Tuttle, G. L. Bakris, R. W. Bilous et al., “Diabetic kidney disease: a report from an ADA consensus conference,” Diabetes Care, vol. 37, no. 10, pp. 2864–2883, 2014.
[15] A. J. Boulton, A. I. Vinik, J. C. Arezzo et al., “Diabetic neuropathies: a statement by the American Diabetes Association,” Diabetes Care, vol. 28, pp. 956–962, 2005.
[16] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003.
[17] P. Pierre-Francois and B. Liesbeth, “Diagnosis and treatment of renal artery stenosis,” Nature reviews Nephrology, vol. 6, no. 3, pp. 151–159, 2010.
[18] L. Chen and Y. Zhou, “Progress in ultrasound diagnosis of renal artery stenosis,” China Practical Medicine, vol. 2, pp. 115–116, 2008.
[19] M. T. Caps, C. Perissinotto, R. E. Zierler et al., “Prospective Study of Atherosclerotic Disease Progression in the Renal Artery,” Circulation, vol. 98, no. 25, pp. 2866–2872, 1998.
[20] T. Zeller, C. Müller, U. Frank et al., “Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis,” Catheterization and Cardiovascular Interventions, vol. 58, no. 4, pp. 510–515, 2003.
[21] X. Zhang, H. Zhou, and Y. Li, “Combined detection of urinary micro albumin, α1-microglobulin and N-acetyl-β-D-glucosaminidase in the early diagnosis of diabetic nephropathy,” Pakistan journal of medical sciences, vol. 33, no. 6, pp. 1324–1327, 2017.
[22] K. Lee, I. B. Park, S. H. Yu et al., “Characterization of variable presentations of diabetic ketoacidosis based on blood ketone levels and major society diagnostic criteria: a new view point
on the assessment of diabetic ketoacidosis,” *Diabetes, metabolic syndrome and obesity: targets and therapy*, vol. 12, pp. 1161–1171, 2019.

[23] World Health Organisation, *Guidelines for controlling and monitoring the tobacco epidemic, Tobacco or Health Programme*, WHO, Geneva, 1997.

[24] H. Liang, J. Wang, H. Xiao et al., “Estimation of cancer incidence and mortality attributable to alcohol drinking in China,” *BMC Public Health*, vol. 10, p. 730, 2010.

[25] E. Kutoh and J. Hayashi, “Effect of canagliflozin on heart function involving ketone bodies in patients with type 2 diabetes,” *Drug research*, vol. 69, no. 5, pp. 297–300, 2019.

[26] F. Prattichizzo, V. De Nigris, S. Micheloni, L. La Sala, and A. Ceriello, “Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component?,” *Diabetes, Obesity and Metabolism*, vol. 20, no. 11, pp. 2515–2522, 2018.

[27] L. C. Gormsen, S. Swart, H. H. Thomsen et al., “Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study,” *Journal of the American Heart Association*, vol. 6, no. 3, 2017.

[28] R. C. Schugar, A. R. Moll, D. A. d’Avignon, C. J. Weinheimer, A. Kovacs, and P. A. Crawford, “Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling,” *Molecular metabolism*, vol. 3, no. 7, pp. 754–769, 2014.

[29] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.

[30] M. Tochiya, H. Makino, T. Tamamata et al., “Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: a pilot study,” *Journal of diabetes investigation*, vol. 11, no. 2, pp. 400–404, 2020.

[31] K. Tziomalos, V. G. Athyros, A. Karagiannis, and D. P. Mikhailidis, “Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 20, no. 2, pp. 140–146, 2010.

[32] L. Petrica, A. Vlad, M. Petrica et al., “Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus,” *Diabetes Research and Clinical Practice*, vol. 94, no. 1, pp. 22–32, 2011.

[33] Y. Dong, W. P. Wang, P. Lin, P. Fan, and F. Mao, “Assessment of renal perfusion with contrast-enhanced ultrasound: preliminary results in early diabetic nephropathies,” *Clinical Hemorheology and Microcirculation*, vol. 62, no. 3, pp. 229–238, 2016.

[34] J. A. Silva, “Evaluation and approach to treatment of renal artery stenosis in patients with diabetic nephropathy,” *Current Diabetes Reports*, vol. 8, no. 6, pp. 494–498, 2008.

[35] J. C. Li, Y. X. Jiang, S. Y. Zhang, L. Wang, Y. S. Ouyang, and Z. H. Qi, “Evaluation of renal artery stenosis with hemodynamic parameters of Doppler sonography,” *Journal of Vascular Surgery*, vol. 48, no. 2, pp. 323–328, 2008.

[36] M. Provenzano, L. Rivoli, C. Garofalo et al., “Renal resistive index in chronic kidney disease patients: possible determinants and risk profile,” *PLoS One*, vol. 15, no. 4, article e0230020, 2020.

[37] A. Abdul Kadir, K. Clarke, and R. D. Evans, “Cardiac ketone body metabolism,” *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1866, no. 6, p. 165739, 2020.

[38] Y. Mizuno, E. Harada, H. Nakagawa et al., “The diabetic heart utilizes ketone bodies as an energy source,” *Metabolism*, vol. 77, pp. 65–72, 2017.

[39] B. Yang, Y. Zhu, D. Xiaodong, M. Sui, and X. Yin, “Increased renal artery resistance index must represent increased renal artery circulation resistance,” in *The 30th Anniversary of the Chinese Society of Ultrasound Medical Engineering and the 12th National Compilation of Papers of the Academic Conference on Ultrasound Medicine*, p. 822, Xi’an, Shaanxi, China, 2014.

[40] A. Saito, R. Kaseda, M. Hosojima, and H. Sato, “Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes,” *International journal of nephrology*, vol. 2011, Article ID 957164, 2010.

[41] R. Malhotra, T. Craven, W. T. Ambrosius et al., “Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT,” *American Journal of Kidney Diseases*, vol. 73, no. 1, pp. 21–30, 2019.

[42] S. H. Park, M. A. Farooq, S. Gaertner et al., “Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat,” *Cardiovascular Diabetology*, vol. 19, no. 1, p. 19, 2020.

[43] R. Bertinat, F. Nualart, and A. J. Yáñez, “SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule?,” *Journal of cellular physiology*, vol. 231, no. 8, pp. 1635–1637, 2016.

[44] L. De Nicola, F. B. Gabbai, M. E. Liberti, A. Sagliocca, G. Conte, and R. Minutolo, “Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes,” *American Journal of Kidney Diseases*, vol. 64, no. 1, pp. 16–24, 2014.

[45] S. J. Chen, L. L. Lv, B. C. Liu, and R. N. Tang, “Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease,” *Cell Proliferation*, vol. 53, no. 3, article e12763, 2020.

[46] E. Yeoh, B. K. Lim, S. Fun et al., “Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients,” *Nephrology*, vol. 23, no. 3, pp. 264–268, 2018.

[47] E. Kornelius, S. C. Lo, C. N. Huang, Y. H. Wang, and Y. S. Yang, “Association of blood glucose and renal end points in advanced diabetic kidney disease,” *Diabetes Research and Clinical Practice*, vol. 161, p. 108011, 2020.